Cargando…

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group

Systemic AL (light chain) amyloidosis is a rare protein misfolding disorder associated with plasma cell dyscrasia affecting various organs leading to organ dysfunction and failure. The Amyloidosis Forum is a public–private partnership between the Amyloidosis Research Consortium and the US Food and D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizio, Avery A, White, Michelle K, D’Souza, Anita, Hsu, Kristen, Schmitt, Paula, Quock, Tiffany P, Signorovitch, James, Lousada, Isabelle, Sanchorawala, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202704/ https://www.ncbi.nlm.nih.gov/pubmed/37229285 http://dx.doi.org/10.2147/PROM.S399658

Ejemplares similares

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis
por: Lousada, Isabelle
Publicado: (2020)

Work Outcomes Among Patients with Light Chain (AL) Amyloidosis: Findings from Three Patient Cohorts
por: Rizio, Avery A, et al.
Publicado: (2021)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Association Between Hematologic Response and Change in Health-Related Quality of Life Among Patients with Light-Chain (AL) Amyloidosis
por: Rizio, Avery A, et al.
Publicado: (2023)

Content Validation of the ATTR Amyloidosis Patient Symptom Survey: Findings from Patient and Clinician Cognitive Debriefing Interviews
por: Rizio, Avery A, et al.
Publicado: (2020)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
por: Maurer, Mathew S., et al.
Publicado: (2022)

Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
por: McCausland, Kristen L., et al.
Publicado: (2019)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States
por: Quock, Tiffany P, et al.
Publicado: (2019)

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
por: Mauermann, Michelle L., et al.
Publicado: (2023)

In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database
por: Quock, Tiffany P, et al.
Publicado: (2022)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
por: Sanchorawala, Vaishali
Publicado: (2022)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

Content validation of the SF-36v2® health survey with AL amyloidosis patients
por: White, Michelle K., et al.
Publicado: (2017)

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
por: Staron, Andrew, et al.
Publicado: (2020)

Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients’ narratives on medical students’ knowledge, attitudes, and behavioral intent
por: Adebayo, Adebanke L., et al.
Publicado: (2023)

Detection of minimal residual disease by next generation sequencing in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2021)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
por: Lovley, Andrew, et al.
Publicado: (2021)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
por: White, Michelle K, et al.
Publicado: (2017)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
por: Staron, Andrew, et al.
Publicado: (2021)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
por: Merlini, G, et al.
Publicado: (2016)

Recent advances in understanding and treating immunoglobulin light chain amyloidosis
por: Badar, Talha, et al.
Publicado: (2018)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

AL Amyloidosis
por: Desport, Estelle, et al.
Publicado: (2012)

Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022)

The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure
por: O’Connor, Meaghan, et al.
Publicado: (2023)

A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
por: Lu, Rebecca, et al.
Publicado: (2022)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

AL Amyloidosis: Unfolding a Complex Disease
por: Lu, Rebecca, et al.
Publicado: (2019)

Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hug2mphau577j77io1m244kfaa